Casper W F van Eijck
Overview
Explore the profile of Casper W F van Eijck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wismans L, de Vries R, van Eijck C, Verheij M, Bogers S, Aerts J, et al.
HPB (Oxford)
. 2025 Mar;
PMID: 40032539
Background: Patients with pancreatic ductal adenocarcinoma (PDAC) are at increased risk for severe COVID-19. Although COVID-19 vaccines are highly recommended for this population, studies on immunogenicity are lacking. We aimed...
2.
van Eijck C, Ju J, van t Land F, Verheij M, Li Y, Stubbs A, et al.
Pancreatology
. 2024 Sep;
24(7):1057-1065.
PMID: 39218754
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Presently, only a fraction of patients undergo successful surgical resection, the most effective treatment. Enhancing treatment strategies...
3.
van Eijck C, Real F, Malats N, Vadgama D, van den Bosch T, Doukas M, et al.
Cell Rep Med
. 2024 May;
5(5):101557.
PMID: 38733987
This study underscores GATA6's role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation. In a...
4.
Rupp L, Dietsche I, Kiessler M, Sommer U, Muckenhuber A, Steiger K, et al.
Front Immunol
. 2024 Apr;
15:1378190.
PMID: 38629072
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at advanced stages and associated with early distant metastasis and poor survival. Besides clinical factors, the tumor microenvironment (TME) emerged as a crucial...
5.
van Eijck C, Vadgama D, van Eijck C, Wilmink J
J Natl Cancer Inst
. 2024 Mar;
116(8):1374-1383.
PMID: 38530777
Background: Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant exploration in treating pancreatic cancer. This study aimed to investigate the influence of metformin on...
6.
van Eijck C, Haddaoui H, Kucukcelebi S, Vadgama D, Fellah A, Mustafa D, et al.
Clin Cancer Res
. 2024 Mar;
30(16):3447-3458.
PMID: 38488815
Purpose: Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential...
7.
van Eijck C, Sabroso-Lasa S, Strijk G, Mustafa D, Fellah A, Groot Koerkamp B, et al.
Neoplasia
. 2024 Feb;
49:100975.
PMID: 38335839
Background: Pancreatic ductal adenocarcinoma (PDAC) is often treated with FOLFIRINOX, a chemotherapy associated with high toxicity rates and variable efficacy. Therefore, it is crucial to identify patients at risk of...
8.
van Eijck C, Strijk G, Vietsch E, van der Sijde F, Verheij M, Mustafa D, et al.
Eur J Cancer
. 2023 Nov;
196:113440.
PMID: 37988843
Background: FOLFIRINOX chemotherapy has improved outcomes for pancreatic cancer patients, but poor long-term survival outcomes and high toxicity remain challenges. This study investigates the impact of FOLFIRINOX on plasma proteins...
9.
van Eijck C, Mustafa D, Vadgama D, de Miranda N, Groot Koerkamp B, van Tienhoven G, et al.
Gut
. 2023 Sep;
73(2):311-324.
PMID: 37709493
Background: This study investigates sex disparities in clinical outcomes and tumour immune profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection preceded by gemcitabine-based neoadjuvant...
10.
de Koning W, van Eijck C, van der Sijde F, Strijk G, Oostvogels A, Debets R, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686626
Introduction: Monitoring the therapeutic response of pancreatic ductal adenocarcinoma (PDAC) patients is crucial to determine treatment strategies. Several studies have examined the effectiveness of FOLFIRINOX as a first-line treatment in...